NEW
YORK, July 14, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities
fraud allegations has commenced on behalf of
shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/tandem-class-action-loss-submission-form/?id=42098&from=4
Further details on the investigation: The investigation
focuses on whether Tandem issued false and/or misleading statements
and/or failed to disclose information pertinent to investors. After
the market closed on November 2,
2022, Tandem released its third quarter 2022 results. The
Company held a conference call on the same day to discuss its third
quarter 2022 financial and operating results. Tandem substantially
lowered its guidance for the year during the call. In response to
the earnings news, market analysts downgraded Tandem and its stock
price fell $14.57 per share, from
$51.34 per share on November 2, 2022 to close at $36.77 per share on November 3, 2022.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/tndm-fraud-alert-jakubowitz-law-is-investigating-tandem-diabetes-care-inc-in-connection-with-potential-violations-of-federal-securities-laws-301877142.html
SOURCE Jakubowitz Law